Structural studies on G protein-coupled receptors (GPCRs) provide important insights into the architecture and function of these important drug targets. However, the crystallization of GPCRs in active states is particularly challenging, requiring the formation of stable and conformationally homogeneous ligand-receptor complexes. Native hormones, neurotransmitters, and synthetic agonists that bind with low affinity are ineffective at stabilizing an active state for crystallogenesis. To promote structural studies on the pharmacologically highly relevant class of aminergic GPCRs, we here present the development of covalently binding molecular tools activating G s -, G i -, and G q -coupled receptors. The covalent agonists are derived from the monoamine neurotransmitters noradrenaline, dopamine, serotonin, and histamine, and they were accessed using a general and versatile synthetic strategy. We demonstrate that the tool compounds presented herein display an efficient covalent binding mode and that the respective covalent ligand-receptor complexes activate G proteins comparable to the natural neurotransmitters. A crystal structure of the β 2 -adrenoreceptor in complex with a covalent noradrenaline analog and a conformationally selective antibody (nanobody) verified that these agonists can be used to facilitate crystallogenesis. (1), and the resulting biochemical instability of the solubilized protein (2, 3). Protein crystallography, the most powerful tool for the study of GPCR structure, requires the formation of stable and conformationally homogeneous ligand-receptor complexes (4). High-affinity agonists with dissociation constants in the low to subnanomolar range and low off-rates facilitate stabilization of the protein throughout the process of expression, purification, and crystallogenesis (2); however, endogenous neurotransmitters usually show poor binding affinity. Low binding affinity with rapid association and dissociation rates leads to conformational heterogeneity that prevents the formation of diffraction-quality crystals. The rapid dissociation rate of agonists also makes it difficult to generate active-state stabilizing proteins, such as the camelid antibodies (nanobodies) that have been used to obtain active-state structures of the β 2 -adrenergic receptor (β 2 AR) (5) and M2 muscarinic receptor (6).
Structural studies on G protein-coupled receptors (GPCRs) provide important insights into the architecture and function of these important drug targets. However, the crystallization of GPCRs in active states is particularly challenging, requiring the formation of stable and conformationally homogeneous ligand-receptor complexes. Native hormones, neurotransmitters, and synthetic agonists that bind with low affinity are ineffective at stabilizing an active state for crystallogenesis. To promote structural studies on the pharmacologically highly relevant class of aminergic GPCRs, we here present the development of covalently binding molecular tools activating G s -, G i -, and G q -coupled receptors. The covalent agonists are derived from the monoamine neurotransmitters noradrenaline, dopamine, serotonin, and histamine, and they were accessed using a general and versatile synthetic strategy. We demonstrate that the tool compounds presented herein display an efficient covalent binding mode and that the respective covalent ligand-receptor complexes activate G proteins comparable to the natural neurotransmitters. A crystal structure of the β 2 -adrenoreceptor in complex with a covalent noradrenaline analog and a conformationally selective antibody (nanobody) verified that these agonists can be used to facilitate crystallogenesis. (1) , and the resulting biochemical instability of the solubilized protein (2, 3) . Protein crystallography, the most powerful tool for the study of GPCR structure, requires the formation of stable and conformationally homogeneous ligand-receptor complexes (4) . High-affinity agonists with dissociation constants in the low to subnanomolar range and low off-rates facilitate stabilization of the protein throughout the process of expression, purification, and crystallogenesis (2); however, endogenous neurotransmitters usually show poor binding affinity. Low binding affinity with rapid association and dissociation rates leads to conformational heterogeneity that prevents the formation of diffraction-quality crystals. The rapid dissociation rate of agonists also makes it difficult to generate active-state stabilizing proteins, such as the camelid antibodies (nanobodies) that have been used to obtain active-state structures of the β 2 -adrenergic receptor (β 2 AR) (5) and M2 muscarinic receptor (6) .
To prevent ligand dissociation, irreversible ligation of electrophilic moieties like halomethylketones, isothiocyanates, Michael acceptors, or aziridinium groups of small-molecule ligands with a suitably positioned nucleophilic residue in the receptor has been used (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . However, irreversible ligands often suffer from incomplete cross-linking (15) and reduced receptor activation when covalent binding leads to loss of agonist efficacy (10, 16) . Furthermore, their highly electrophilic nature and the abundance of nucleophilic groups in biological systems may lead to a low coupling selectivity (7, 8) .
Disulfide-based cross-linking approaches (17, 18) offer the advantage that the covalent binding of disulfide-containing compounds is chemoselective for cysteine and enforced by the affinity of the ligand-pharmacophore rather than by the electrophilicity of the cross-linking function (19) . We refer to the described ligands as covalent rather than irreversible agonists because cleavage may be promoted by reducing agents and the disulfide transfer process is a reversible chemical reaction in general.
Structural information on the target protein facilitates the development of covalent ligand-receptor pairs. Mutation of H93 2.64 in the β 2 AR to cysteine introduced an anchor for the disulfidebased covalent agonist FAUC50, which does not perturb ligand binding or the activation of the receptor, and thus enabled, to our knowledge, the first agonist-bound GPCR structure (20) . Taking advantage of the high structural homology among aminergic GPCRs, we reasoned that the introduction of cysteine into position X 2.64 should also result in a covalently binding receptor mutant for other aminergic GPCRs.
We here report a methodology to generate disulfide-based covalent ligand-receptor pairs to promote structural and functional studies on GPCRs. We demonstrate that even the lowaffinity endogenous agonists noradrenaline, dopamine, and serotonin can be converted into efficient covalently binding
Significance
Protein crystallography has greatly contributed to our understanding of the structure and function of G protein-coupled receptors (GPCRs). Recent success in the structural investigation of active GPCR conformations was guided by the application of high-affinity agonists and G proteins or G protein mimetic nanobodies. However, poor affinities of agonists prevent the formation of diffraction-quality crystals and hamper the generation of state-specific nanobodies. To overcome this limitation, we present a general approach to covalently binding molecular tools for the construction of stable ligand-receptor complexes capable of G protein activation. Besides the promotion of structural studies, tethered agonist-GPCR complexes may find application in biochemical and biophysical experiments that require reliable labeling of distinct receptor populations, underlining the versatility of covalent agonists for studying GPCR activation. molecular tools for the β 2 AR, the dopamine D 2 receptor (D 2 R), and the 5-hydroxytryptamine 2A (5-HT 2A ) serotonergic subtype representing G s -, G i -, and G q -coupled GPCRs, respectively. Analogous studies were conducted starting from histamine and the receptor subtype H 1 . We applied this strategy to obtain an active-state crystal structure of the β 2 AR H93C and a covalent (nor)adrenaline analog.
Results
Design and Synthesis of the Covalent Agonists. The designed covalent ligands feature the recognition element of neurotransmitters connected to a disulfide moiety via a flexible linker, based on the parent compound FAUC50 (Fig. 1) . To develop a general approach to covalent ligands, we planned to exploit the naturally installed nucleophilicity of the neurotransmitters in a chemoselective N-alkylation reaction. Starting from a substituted hydroxyphenylethanol, the required electrophilic building blocks were synthesized ( Fig. 1 and SI Appendix, Fig. S3 ). The chemoselective N-alkylation reaction of the biogenic amines was initially hampered by the instability of the catechol and the 5-hydroxyindole moiety of the endogenous ligands and the disulfide-functionalized derivatives. Catechol groups, for instance, are susceptible to oxidizing conditions, irradiation, and heat, leading to a complex mixture of oxidization products (21) . Thus, adjustment of solvent, base, temperature, and handling under an inert atmosphere was necessary to guarantee a good balance between consumption of the starting material and low degradation of the products. Subsequent disulfide exchange and immediate purification by preparative HPLC efficiently yielded the corresponding covalent (nor)adrenaline (1 and 2), dopamine (3), and histamine (5) derivatives (SI Appendix, Fig. S1 ). Because the serotonergic analog (4) showed substantial impurities, intermediate silyl-protection of the phenolic moiety was necessary to access the pure product (SI Appendix, Fig. S2 ). Despite their immanent sensitivity to oxygen, irradiation, and heat, all derivatives could be obtained in high quality, as determined by NMR.
Characterization of the Covalent Ligand-Receptor Pairs. To construct covalent GPCR-neurotransmitter complexes, our initial investigations were directed to the linkage of the β 2 AR H93C and the disulfide-functionalized (nor)adrenaline analogs 1 and 2, slightly differing in their spacer length. The efficiency of these compounds in the formation of the covalent bond was evaluated in a time-dependent radioligand depletion assay. Therefore, we used WT β 2 AR with a single H93C mutation that was purified and reconstituted into HDL particles (22) . Both ligands showed considerable covalent binding after incubation with the mutated receptor that could not be reversed by a large excess of radioligand ( Fig. 2A and SI Appendix, Fig. S5 ). Compound 2 was equally effective as FAUC50 in blocking radioligand binding, whereas analog 1 displayed a lower propensity for covalent complex formation, indicating that a shorter linker results in a higher degree of covalent linkage (SI Appendix, Figs. S4 and S5). To determine whether the tethered ligand-receptor complex is capable of activating heterotrimeric G s protein, reconstituted WT and β 2 AR H93C mutant receptors were incubated with ligand 2 alone or with ligand 2 followed by an excess of the highaffinity inverse agonist ICI-118,551. After addition of G protein, activation was observed by measuring [ 35 S]GTPγS binding to the Gα s subunit. Fig. 2D shows that an excess of the inverse agonist ICI-118,551 is unable to reverse compound 2-induced G protein activation in the case of β 2 AR H93C but prevented agonistinduced nucleotide exchange by the WT receptor. Thus, the disulfide-functionalized (nor)adrenaline 2 forms a stable complex with the β 2 AR H93C that promotes G protein activation. To investigate covalent receptor binding and activation of the disulfide-functionalized dopamine analog 3, the D 2 R was chosen as a representative model for a G i -coupled GPCR and the mutation L94C
2.64 was introduced into WT D 2 R. A radioligand depletion assay, using membranes containing the D 2 R L94C mutant, revealed extensive blockade of [ 3 H]spiperone binding at the mutated receptor, suggesting a highly efficient covalent binding mode for the dopamine analog 3 (Fig. 2B) . The ability of dopamine analog 3 to activate WT D 2 R, as well as the ability of the covalent 3-D 2 R L94C complex to induce G protein-promoted signaling, was assessed in an inositol phosphate (IP) formation assay using HEK cells transiently transfected with a chimeric Gα qi5 protein and the WT and mutant receptor, respectively (6, 23) (Fig. 2D and SI Appendix, Fig. S6 ). In contrast to the reversibility of the control noncovalent agonist quinpirole, agonistinduced IP accumulation by the dopamine analog 3 could not be diminished by an excess of antagonist (Fig. 2D) , demonstrating that the dopamine analog 3 is an efficacious covalent agonist for the D 2 R.
To extend our strategy to a G q protein-coupling subtype, the serotonin receptor mutant 5-HT 2A T134C was generated from WT receptor to evaluate the disulfide-functionalized serotonin surrogate 4. Interestingly, we observed only minor blockade of this receptor mutant in the radioligand depletion assay (SI Appendix, Fig. S7 ). This result prompted us to evaluate the role of serine residue 131 in transmembrane helix 2 (TM2), positioned below the cysteine anchor, in sterically hindering efficient covalent binding. Consequently, S131
2.61 was mutated to glycine. Investigation of the double-mutant 5-HT 2A S131G-T134C revealed that the amount of covalently modified receptor increased in the radioligand depletion assay ( accumulation assays indicated substantial nonreversible G q protein activation by the covalent neurotransmitter-receptor complex ( Fig. 2D and SI Appendix, Fig. S8) .
Investigation of the covalent histamine analog 5 directed us to the construction of the histamine H 1 receptor mutant H 1 R Y87C as an additional example of a G q -coupled GPCR. In a corresponding IP accumulation assay, histamine and histamine analog 5 show comparable activation of WT and mutant receptors (SI Appendix, Figs. S9 and S10). Although the response of histamine can be substantially reduced by an excess of the antagonist diphenhydramine, histamine analog 5 still displays significant Gα q activation, thus demonstrating considerable formation of a covalent ligand-receptor complex (SI Appendix, Fig. S10 ). To test the applicability of our methodology in structural studies, we conducted crystallography trials for β 2 AR H93C using compound 2 and the engineered nanobody 6B9 (Nb6B9), which is a high-affinity version of a single-domain antibody fragment obtained from llamas that was further evolved to display optimized properties for crystallography (24) . Nb6B9 mimics the G protein by binding at the intracellular surface of the β 2 AR, and thus stabilizes the active state of the receptor (Fig. 3A) . Crystals of the compound 2-bound β 2 AR H93C -Nb6B9 complex, grown in lipidic mesophase (25) , displayed excellent size and stability at 20°C, in contrast to the crystals obtained for the adrenaline-bound complex of β 2 AR, stabilized by Nb6B9 (24), which were inherently unstable and had to be harvested shortly after their appearance.
The structure of the compound 2-bound β 2 AR-Nb6B9 complex was solved at a resolution of 3.3 Å with clear electron density for the covalent ligand (SI Appendix, Fig. S11 ). It reveals a remarkable similarity to the 3.2 Å adrenaline-bound structure. Fig. 3B shows a superimposition of the binding pocket of both complexes. The adrenaline-pharmacophores form identical ionic and hydrophilic interactions. A unique feature of catechol-bound structures is the tilt of TM6 toward the catechol moiety to form a hydrogen bond between the meta-hydroxyl group and Asn293 6.55 (24) (SI Appendix, Fig. S12 ). In the adrenaline-bound structure, a water molecule further mediates an extended hydrogen bond network from Asn293 6.55 to His296 6.58 and up to Asn301 in extracellular loop 3 (ECL3) (Fig. 3B) . The electron density of the covalent complex structure is suggestive of the existence of a corresponding water molecule but is insufficient to confirm its presence definitively. His296 6.58 and the Asn301 in ECL3 appear to adopt different positions in the covalent complex structure; however, the electron density maps for this region are relatively weak, which may reflect the inherent flexibility of ECL3.
The linker of the covalent ligand is positioned in an extended pocket formed by TM3, TM7, and ECL2 (SI Appendix, Fig. S13) . A comparison of the orthosteric and extended pocket of the adrenaline-and compound 2-bound structures illustrates that the covalent ligand perfectly fills additional space without altering the overall shape of the adrenaline pocket (Fig. 3C) . Despite wt is reduced to basal activity by adding an excess of inverse agonist ICI-118,551 (ICI), whereas the compound 2-β 2 AR H93C complex displays significant nucleotide binding even in presence of ICI-118,551. An IP accumulation assay was conducted to measure activation of compound 3 at D 2 R L94C in comparison to the reference quinpirole (quin). Although the effect of quinpirole is fully blocked by an excess of the antagonist haloperidol (halo), the compound 3-D 2 R L94C complex induces stable and nonreversible IP formation. Similarly, IP accumulation of compound 4 reveals substantial activation of 5-HT 2A S131C-T134C , which is equal to the effect of serotonin (serot), but cannot be inhibited by the antagonist ketanserin (ketan). Data represent the mean of three experiments ± SEM, each performed in triplicate.
minor differences in ECL3 of the β 2 AR, our approach yielded a structure that is virtually identical to the adrenaline-β 2 AR complex.
Discussion
Endogenous neurotransmitters typically bind with a low affinity to their respective receptors. Thus, obtaining active structures often requires synthetic high-affinity agonists. However, appropriate agonists may not be available or may not stabilize physiological conformations. This study presents a general and practical approach for conversion of the native neurotransmitters noradrenaline, dopamine, serotonin, and histamine into covalent GPCR agonists. The convergent synthetic strategy facilitates fast and facile access to the respective disulfide-functionalized molecular tools, allowing one to optimize the linker length between the pharmacophore and the cross-linking functionality (SI Appendix, Figs. S1, S4, and S5). By using different head groups endowed with a primary or secondary amine, this general synthetic approach provides access to a variety of tailored covalent ligands for aminergic GPCRs.
The formation of covalent ligand-receptor complexes was evaluated in radioligand depletion assays for compounds 2, 3, and 4. In addition to synthetic modification of the compounds, the mutation of amino acid residues in proximity to the disulfideforming cysteine, perturbing covalent bond formation provides an additional tool with which to optimize the target complex. Functional assays confirmed the covalent binding mode for all described agonists and, most importantly, the ability of the covalent ligand-receptor pairs to activate G proteins.
The applicability of the covalent agonists in structural studies is demonstrated by the active-state crystal structure of β 2 AR H93C in complex with a covalent (nor)adrenaline-derived agonist, verifying that the designed ligands can be used to facilitate crystallogenesis.
A comparison of the presented structure and the adrenaline-bound structure revealed that compound 2 induces a virtually identical receptor conformation, providing evidence that the covalent agonists can yield structural insights into the binding mode of endogenous agonists.
In addition to their benefit in structural studies, covalent agonists can find application in biophysical and biochemical assays that require stable ligand-receptor complexes. Although the crystallization of GPCR-G protein complexes is still notoriously difficult (4, 26, 27) , a recent key strategy to obtain activestate structures comprised the use of conformationally selective nanobodies that serve as G protein mimetics and stabilize active conformations (5, 6, 24) . Covalent ligand-receptor complexes can be useful for the generation of G protein-mimicking nanobodies because they prevent ligand dissociation during the immunization of llamas (28) .
A mustard-based covalent agonist FAUC123 facilitated the identification of a rare G protein mimetic nanobody for the M2 muscarinic receptor from a yeast display library using fluorescence-activated cell sorting. The covalent agonist enabled simultaneous staining of yeast with both agonist-and inverse agonist-occupied M2 receptor populations, which were distinguishably labeled with separate fluorophores (6). The disulfidebased approach will further extend the scope and complement the conformational selection of nanobodies.
This strategy may also be useful for studying oligomerization of aminergic GPCRs and allosteric interactions between protomers. In a system that coexpresses WT receptor and a corresponding X2.64C mutant, a covalent complex of a disulfidebased agonist and the mutant receptor could be formed selectively. One could then examine the functional properties of the WT receptor in the presence and absence of receptor bound to covalent agonist.
In conclusion, we demonstrated the generation of efficacious disulfide-based covalent agonists for aminergic GPCRs representing examples for G s -, G i -, and G q -coupled receptors. We believe that this general and adaptable strategy provides a framework for the development of novel covalent agonists for this class of receptors. Applications of covalent ligands extend well beyond structural biology, highlighting their versatility and utility in promoting structural and functional studies on GPCRs.
Materials and Methods
Synthesis and Characterization of the Covalent Agonists. Detailed schemes and conditions for the synthesis of covalent agonists 1-5 are provided in SI Appendix, Figs. S1 and S2. The synthesis of additional intermediates is summarized in SI Appendix, Fig. S3 . Detailed methods and characterization for all compounds are provided in SI Appendix, SI Note S1.
1 H and 13 C NMR spectra for covalent agonists 1-5 are provided in SI Appendix, SI Note S2. β 2 AR Expression and Purification. For functional experiments, human β 2 AR bearing an amino-terminal FLAG epitope tag truncated after residue 365 and with or without an H93C mutation was expressed in Sf9 cells using the FastBac baculovirus system (Expression Systems). Receptor was extracted and purified as described previously (24, 29) (details are provided in SI Appendix, SI Materials and Methods). For crystallographic experiments, a construct of human β 2 AR fused to an N-terminal T4 lysozyme (30) containing an H93C mutation was expressed and purified from Sf9 insect cells. After purification, the receptor was incubated for 60 min at room temperature with a stoichiometric excess of compound 2. A 1.3-fold molar excess of Nb6B9 was then added and incubated for an additional 30 min. The sample was then concentrated using a 50-kDa spin concentrator and purified over a Sephadex S200 size-exclusion column (GE Healthcare) (details are provided in SI Appendix, SI Materials and Methods).
Expression and Purification of Nb6B9. Nanobody was expressed in Escherichia coli and purified as described previously (5) Crystallization, Data Collection, and Refinement of the 2-β 2 AR H93C -Nb6B9
Complex. Crystals were grown in lipid mesophase using , and H 1 Y87C receptors was studied using IP accumulation assays as described (6, 23) . For activation studies with G i -coupled GPCRs, HEK 293 cells were transiently cotransfected with cDNA encoding for D 2 R L94C and the hybrid G protein Gα qi5 (Gα q protein with the last five amino acids at the C terminus replaced by the corresponding sequence of Gα i ; a gift from The J. David Gladstone Institutes) (36) . Cells were preincubated with myo-[
3 H]inositol (specific activity = 22.5 Ci·mmol −1 ; PerkinElmer) for 15 h. After incubation with compound 3 for 30 min, the antagonist haloperidol was added to half of the samples (buffer was added to the other half). Incubation was continued for additional 150 min, and total IP was determined (details are provided in SI Appendix, SI Materials and Methods). Activation studies with a G q -coupled GPCR were done with HEK 293 cells, which were transiently transfected with cDNA encoding for the 5-HT 2A S131G-T134C or H 1 Y87C receptor, respectively, similar to the described method (details are provided in SI Appendix, SI Materials and Methods). After incubation of 5-HT 2A S131G-T134C with compound 4 and serotonin for 90 min, ketanserin was added to half of the samples to inhibit further receptor activation. After further incubation for 150 min, total IP was determined as described. Likewise, the H 1 Y87C receptor was incubated with compound 5 and histamine for 90 min, and diphenhydramine was then added to half of the samples (details are provided in SI Appendix, SI Materials and Methods).
